A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130312225352im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
This is a study to determine what Human Papillomavirus HIV seropositive women in Botswana, South Africa and Brasil have been exposed to during their life. The Human Papillomavirus causes cervical cancer. Different types are more likely to lead to cancer than other types. A vaccine has been made to fight infection against HPV 16 and 18 which has been shown to cause cervical cancer in America and Europe. What HPV type cause cancer in other countries is not as well studied.
Hypothesis HPV serology will demonstrate that exposure to each HPV type in Gardisil (6,11,16,18) will be <50% in HIV seropositive women in resource limited countries.
Condition |
---|
HIV HIV Infections |
Study Type: | Observational |
Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
Official Title: | A Pilot Observational Study to Determine the Prevalence of HPV Serology in HIV Seropositive Women From Subsaharan Africa and Brasil |
- To determine the seroprevalence of HPV types 6,11,16,18 in HIV serOpositive women for Botswana, South Africa and Brazil [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Biospecimen Retention: None Retained
Blood /plasma specimen 10cc
Enrollment: | 487 |
Study Start Date: | February 2009 |
Study Completion Date: | December 2010 |
Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
1
HIV seropositive women from an HIV Antiretroviral therapy clinic in Johannesburg South Africa
|
2
A cohort of HIV seropositive women from Gabarone Botswana
|
3
A cohort of HIV seropositive women from Rio De Janeiro Brasil
|
Detailed Description:
Plasma from HIV seropositive women will be taken and sent to MERCK in the USA to evaluate what the antibody titers of HPV 6,11,16 and 18. .
![](https://webarchive.library.unt.edu/web/20130312225352im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
HIV seropositive women from South Africa, Botswana, and Brasil
Inclusion Criteria:
- HIV seropositive women 18 years of age and older Consent signed per local IRB requirement
Exclusion Criteria:
- Can not give blood
![](https://webarchive.library.unt.edu/web/20130312225352im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Botswana | |
Shahin Lockman | |
Habarone, Botswana | |
Brazil | |
Fundacao Oswaldo Cruz | |
Rio De Janeiro, Brazil | |
South Africa | |
University of Witwatersrand/Helen Joseph Hospital | |
Johannesburg, South Africa |
Principal Investigator: | Cynthia S Firnhaber, MD | Clinical HIV Research Unit University of Witwatersrand |
![](https://webarchive.library.unt.edu/web/20130312225352im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
Responsible Party: | Cynthia S Firnhaber, Associate Professor of Medicine, University of Witwatersrand, South Africa |
ClinicalTrials.gov Identifier: | NCT00840905 History of Changes |
Other Study ID Numbers: | Merck P0806 |
Study First Received: | February 10, 2009 |
Last Updated: | November 6, 2012 |
Health Authority: | South Africa: Human Research Ethics Committee |
Keywords provided by University of Witwatersrand, South Africa:
HPV |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on March 10, 2013